PROTEOMICS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (254)	4/24/2001 5:08:05 AM
From: nigel bates	Read Replies (2) of 539

On the chance of wandering OT... April 24 /PRNewswire/ -- m-phasys GmbH and Graffinity Pharmaceutical Design GmbH today announced an alliance aimed at the development and joint marketing of a novel drug discovery platform for GPCRs (G protein coupled receptors). The companies will offer an integrated discovery platform consisting of m-phasys' M-FOLD refolding technology for GPCRs and Graffinity's chemical microarray aided drug discovery technology. Collaborators will be able to work with m-phasys and Graffinity throughout the drug discovery process from target gene expression through to advanced lead development. Financial terms were not disclosed. ``The human genome project brought us several hundred potential GPCR targets for drug discovery. Our alliance with m-phasys will now allow us to address this important market and deliver novel drug leads for GPCRs to our clients much more rapidly and efficiently when compared to the traditional drug discovery methods,'' says Dr. Dirk Vetter, CEO and co-founder of Graffinity. Dr. Wolfgang Arndt, COO and co-founder of m-phasys stated: ``Small molecules interacting with GPCRs are historically the most potent pharmaceutical drugs. The alliance with Graffinity gives us the opportunity to generate small molecules as lead compounds targeting GPCRs and will add tremendous value to our Compound Generation Network.'' The announcement of a joint technology offering by m-phasys and Graffinity follows extensive technology development by the two companies after signing a letter of intent in February 2001. Notes: m-phasys The vision of m-phasys is to become the leading company for membrane protein drug discovery. Based on its proprietary M-FOLD refolding technology capable of producing large amounts of highly purified membrane proteins out of bacterial cultures, m-phasys has identified two business units: * 1. Lead Discovery Tools * Based on the refolded proteins, m-phasys offers the development of lead * discovery tools to the Life Science Industry. First industrial partner is * GlaxoSmithKline, UK. * 2. Compound Generation Network * m-phasys builds an alliance network of biotech companies with * complementary technologies to M-FOLD with the goal to generate lead * compounds for industrial clients. First alliance contract recently signed * with Cosmix molecular biochemicals, Germany. Graffinity is a German biotech company based in Heidelberg that has taken an innovative approach to drug discovery which will significantly speed up the identification of lead structures. Graffinity's technology platform integrates chemical microarrays and a novel label-free methodology which allows the standardised analysis of proteins with numerous small organic molecules. During the RAISE process molecules are further developed to interact selectively and with high affinity with the target protein. Graffinity is looking for long-term partnerships with pharmaceutical, biotech and agrochemical companies exploiting the full potential of its lead generating platform... For additional corporate information, visit the websites www.m-phasys.com www.graffinity.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next